Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Percheron Therapeutics ( (AU:PER) ) has issued an announcement.
Percheron Therapeutics has disclosed a change in director Ben Gil Price’s holdings, following his on-market purchase of 2 million fully paid ordinary shares on 22 December 2025 for approximately A$17,220, increasing his total shareholding to 7,999,805 shares while his options position remains unchanged. The transaction, which did not occur during a closed period and involved no change in contractual interests, signals increased financial alignment between the director and shareholders and provides additional transparency to investors regarding insider confidence in the company’s prospects.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a listed company in the biotechnology and therapeutics sector, focusing on the development of medical treatments, with its shares traded on the ASX. The company operates in a highly regulated environment where directors’ dealings in securities are closely monitored and disclosed to the market.
Average Trading Volume: 2,943,160
Technical Sentiment Signal: Sell
Current Market Cap: A$8.7M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.